Becton, Dickinson and Company Submits Pre-Market Approval Supplement to FDA for BD Onclarity HPV Test With Extended Genotyping Capabilities
November 12, 2019
November 12, 2019
FRANKLIN LAKES, New Jersey, Nov. 12 -- Becton, Dickinson and Co., a medical technology company, issued the following news release:
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity(TM) HPV Assay.
The FDA-approved BD Onclarity(TM) HPV Assay detects 14 types of hig . . .
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity(TM) HPV Assay.
The FDA-approved BD Onclarity(TM) HPV Assay detects 14 types of hig . . .